Skip to main content
OpenTrials

Clinical trial condition

Moderate-to-severe Atopic Dermatitis

Explore clinical trials studying Moderate-to-severe Atopic Dermatitis. Study availability and eligibility vary by location and protocol.

23 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Moderate-to-severe Atopic Dermatitis trial results

Completed

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04921345

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, Dermatitis, Atopic, +9 more
Locations
  • Galderma Investigational Site #8636 Fountain Valley, California, United States
  • Galderma Investigational Site #9937 San Diego, California, United States
  • Galderma Investigational Site #9930 Vista, California, United States
  • Galderma Investigational Site #9929 Coral Gables, Florida, United States
View all 23 locations
View Trial Details
Completed

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

NCT05590585

Conditions
Atopic Eczema, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +14 more
Locations
  • Total Skin & Beauty Dermatology Center Birmingham, Alabama, United States
  • The University Of Alabama At Birmingham Birmingham, Alabama, United States
  • C2 Research Center, LLC Montgomery, Alabama, United States
  • Center for Dermatology Clinical Research, inc. Fremont, California, United States
View all 30 locations
View Trial Details
Completed

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03985943

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, Dermatitis, Atopic, +9 more
Locations
  • Galderma Investigational Site 8880 North Little Rock, Arkansas, United States
  • Galderma Investigational Site 8578 Cerritos, California, United States
  • Galderma Investigational Site 8636 Fountain Valley, California, United States
  • Galderma Investigational Site 8888 Fullerton, California, United States
View all 174 locations
View Trial Details
Completed

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03989349

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, Dermatitis, Atopic, +9 more
Locations
  • Galderma Investigational Site 8749 Birmingham, Alabama, United States
  • Galderma Investigational Site 8893 Birmingham, Alabama, United States
  • Galderma Investigational Site 8866 Guntersville, Alabama, United States
  • Galderma Investigational Site 8808 Scottsdale, Arizona, United States
View all 138 locations
View Trial Details
Completed

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

NCT05017480

Conditions
Moderate-to-severe Atopic Dermatitis
Locations
  • Connect Investigative Site 33 Hefei, Anhui, China
  • Connect Investigative Site 01 Beijing, Beijing Municipality, China
  • Connect Investigative Site 02 Beijing, Beijing Municipality, China
  • Connect Investigative Site 03 Beijing, Beijing Municipality, China
View all 48 locations
View Trial Details
Completed

Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT05203380

Conditions
Moderate-to-severe Atopic Dermatitis
Locations
  • Clinical Research Center of Alabama, LLC Birmingham, Alabama, United States
  • Arizona Allergy & Immunology Research Gilbert, Arizona, United States
  • Pediatric Skin Research, LLC Coral Gables, Florida, United States
  • Skin Research of South Florida, LLC Miami, Florida, United States
View Trial Details
Completed

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT04444752

Conditions
Moderate-to-severe Atopic Dermatitis
Locations
  • Connect Investigative Site 310 Glendale, Arizona, United States
  • Connect Investigative Site 338 Phoenix, Arizona, United States
  • Connect Investigative Site 316 Tempe, Arizona, United States
  • Connect Investigative Site 305 Little Rock, Arkansas, United States
View all 59 locations
View Trial Details
Completed

Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

NCT04805411

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, Dermatitis, Atopic, +9 more
Locations
  • Beijing Chao-Yang Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Friendship Hospital，Capital Medical University Beijing, Beijing Municipality, China
  • Peking University People's Hospital Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
View all 25 locations
View Trial Details
Completed

Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

NCT04893941

Conditions
Moderate-to-severe Atopic Dermatitis
Locations
  • Second Xiangya Hospital of Central South University Changsha, Hunan, China
  • Wuxi Second Hospital Wuxi, Jiangsu, China
  • West China Hospital of Sichuan University Chengdu, Sichuan, China
  • Hangzhou First People's Hospital Hangzhou, Zhejiang, China
View Trial Details

Related conditions